A Phase One, Open Label, Multi-Dose Study To Evaluate The Safety, Tolerability, And Biologic Effects Of Three Doses Of Iw001 In Patients With Idiopathic Pulmonary Fibrosis (ipf)

被引：0
|
作者：
Rothhaar, K. [1 ]
Chew, T. [1 ]
Frye, S. [1 ]
Klemsz, M. [2 ]
Lange, W. [1 ]
Wilkes, D. S. [2 ]
机构：
[1] ImmuneWorks Inc, Indianapolis, IN USA
[2] Indiana Univ Sch Med, Indianapolis, IN 46202 USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2013年 / 187卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A5709
引用
收藏
页数：1
相关论文
共 44 条
  • [21] Late Breaking Abstract - Phase 2, multi-center, open label, single-arm study of TAS-115, a novel multi-kinase inhibitor in patients with idiopathic pulmonary fibrosis
    Ogura, Takashi
    Nishioka, Yasuhiko
    Saito, Takefumi
    Tomii, Keisuke
    Kamio, Koichiro
    Tomioka, Hiromi
    Hisata, Shu
    Sakamoto, Susumu
    Handa, Tomohiro
    Miyazaki, Yasunari
    Homma, Sakae
    Azuma, Arata
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [22] Phase I/II open-label, multiple-dose, dose-escalation study to evaluate the safety and tolerability of SNS01T administered by intravenous infusion in patients with relapsed or refractory multiple myeloma.
    Lust, John Anthony
    Barranco, Charles
    Lacy, Martha
    Dispenzieri, Angela
    Gertz, Morie A.
    Dingli, David
    Russell, Stephen J.
    Buadi, Francis
    Zeldenrust, Steven R.
    Hayman, Suzanne R.
    Rajkumar, S. Vincent
    Kumar, Shaji
    Usmani, Saad Zafar
    Thompson, John
    Taylor, Catherine
    Dondero, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [23] A Phase 1, Open-Label, Dose-Escalation and Expansion, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MT-0169 in Patients with Relapsed or Refractory Multiple Myeloma or Non-Hodgkin Lymphoma
    Dholaria, Bhagirathbhai
    Mamuye, Admasu
    Yurewicz, Diana
    Dabovic, Kristina
    Yuet, Amy
    Abonour, Rafat
    Kelly, Kevin R.
    Voorhees, Timothy J.
    Kazandjian, Dickran
    BLOOD, 2022, 140 : 12621 - 12622
  • [24] Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma
    Lust, John A.
    Usmani, Saad Z.
    Hamadani, Mehdi
    Barranco, Charles
    Lacy, Martha Q.
    Dispenzieri, Angela
    Gertz, Morie A.
    Dingli, David
    Russell, Stephen
    Buadi, Francis K.
    Zeldenrust, Steven R.
    Hayman, Suzanne R.
    Rajkumar, S. Vincent
    Kumar, Shaji K.
    Thompson, John
    Taylor, Catherine A.
    Dondero, Richard
    BLOOD, 2012, 120 (21)
  • [25] A phase 1 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of MEDI7247 in patients with select relapsed/refractory hematologic malignancies.
    Fathi, Amir Tahmasb
    Donnellan, William Bruce
    Lyons, Roger M.
    Maris, Michael B.
    Kim, Tae Min
    Kim, Won Seog
    Schiller, Gary J.
    Abboud, Camille N.
    Arellano, Martha Lucia
    Cull, Elizabeth H.
    Yee, Karen W. L.
    Townsley, Danielle Michelle
    Wang, Fujun
    Bothos, John G.
    Yao, Nai-Shun
    Salles, Gilles A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] A phase 1, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10382 (TERN-701) in patients (pts) with chronic myeloid leukemia (CML)
    Li, Weiming
    Xu, Na
    Xu, Zhongyuan
    Zhang, Yanli
    Li, Junmin
    Zhu, Huanling
    Zheng, Li
    Yan, Xiaojing
    Du, Xin
    Wei, Hongying
    Huang, Qiqi
    Wei, Jiawei
    Hu, Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [27] A phase 1, open-label, dose-escalation, multicenter study to evaluate the tolerability, safety, pharmacokinetics, and activity of ADCT-301 in patients with relapsed or refractory CD25-positive acute myeloid leukemia.
    Tallman, Martin S.
    Feingold, Jay Marshall
    Spira, Alexander I.
    Rizzieri, David
    Atallah, Ehab L.
    Stock, Wendy
    Jain, Nitin
    Walter, Roland B.
    Chung, Ki Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [28] A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis
    A Dierig
    M Hoelscher
    S Schultz
    L Hoffmann
    A Jarchow-MacDonald
    EM Svensson
    L Te Brake
    R Aarnoutse
    M Boeree
    TD McHugh
    LM Wildner
    X Gong
    PPJ Phillips
    LT Minja
    N Ntinginya
    S Mpagama
    A Liyoyo
    RS Wallis
    M Sebe
    FA Mhimbira
    B Mbeya
    M Rassool
    L Geiter
    YL Cho
    N Heinrich
    Trials, 24
  • [29] A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis
    Dierig, A.
    Hoelscher, M.
    Schultz, S.
    Hoffmann, L.
    Jarchow-MacDonald, A.
    Svensson, E. M.
    Te Brake, L.
    Aarnoutse, R.
    Boeree, M.
    McHugh, T. D.
    Wildner, L. M.
    Gong, X.
    Phillips, P. P. J.
    Minja, L. T.
    Ntinginya, N.
    Mpagama, S.
    Liyoyo, A.
    Wallis, R. S.
    Sebe, M.
    Mhimbira, F. A.
    Mbeya, B.
    Rassool, M.
    Geiter, L.
    Cho, Y. L.
    Heinrich, N.
    TRIALS, 2023, 24 (01)
  • [30] A phase 2, open-label, adaptive, dose-ranging study with long-term extension to evaluate the safety, tolerability, efficacy, and pharmacokinetics of intra-articular AMB-05X injections in patients with tenosynovial giant cell tumor
    Gelderblom, Hans
    Bhadri, Vivek
    Randall, R. Lor
    Scharschmidt, Thomas
    Tap, William D.
    Alani, Laman
    Johnson, Kirk
    Leyva, Stephanie
    Nguyen, Dorothy D.
    Nguyen, Tiffany
    van de Sande, Michiel A. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345